Coherence Neuro
Latest round
- Series A
Last raised
- Oct 2026
Total raised
- $55M
Investors
- 26
About Coherence Neuro
Coherence Neuro, founded in 2022 in San Francisco, US, develops neurotechnological solutions aimed at managing cancer treatment effectively. Ben Woodington (CEO) and Elise Jenkins co-founded the firm. Coherence specializes in advanced therapeutic neurotechnology, primarily through its flagship product, SOMA, a therapeutic brain-computer interface designed to monitor and manage cancer treatment continuously. SOMA operates by administering custom bioelectronic stimulation tailored to the unique physiological characteristics of each patient, aiming to keep cancer in check on a 24/7 basis. The system includes a discreet wireless implant, a minimalist wearable device, and a companion app that delivers real-time insights and symptom tracking. This innovative approach addresses the critical need for personalized, targeted cancer therapies, directly impacting patients’ quality of life by allowing them to manage their treatment discreetly and effectively. Coherence's products are particularly targeted toward oncology patients and healthcare providers seeking to integrate cutting-edge neurotechnological solutions into their treatment plans, with potential markets spanning North America, Europe, and parts of Asia. Coherence generates revenue through the commercialization of its SOMA system, which is structured around direct-to-consumer sales and partnerships with healthcare providers. The company’s business model includes subscription services for ongoing software updates and patient support, ensuring that users receive the latest advancements and personalized care. Revenue transactions involve the sale of the SOMA implant, wearable device, and app, with potential bundled pricing options that encourage comprehensive adoption of the entire system. The firm targets both individual patients and institutional healthcare settings, positioning its services as critical components in modern cancer management strategies. Specific pricing structures for these innovative products reflect their unique therapeutic value and the personalization of treatment they offer. The firm intends to expand its market reach into Europe and parts of Asia by 2025, establishing partnerships with local healthcare providers to facilitate the adoption of its technology.
Who invested in Coherence Neuro
26 investors across 2 rounds
See all investors in Coherence Neuro
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Coherence Neuro
Who invested in Coherence Neuro?
Coherence Neuro has 26 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Coherence Neuro raised?
Coherence Neuro has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Coherence Neuro last raise money?
Coherence Neuro's most recent round on record is a Series A, in Oct 2026.
What does Coherence Neuro do?
Coherence Neuro, founded in 2022 in San Francisco, US, develops neurotechnological solutions aimed at managing cancer treatment effectively.
Where is Coherence Neuro headquartered?
Coherence Neuro is headquartered in San Francisco, US.
Which VCs invest in companies like Coherence Neuro?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back medical devices & equipment companies at Coherence Neuro's stage. Their profiles are linked below.
VCs backing medical devices & equipment startups at Series A
Raising like Coherence Neuro? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.